At a glance
Summary
Teva Pharmaceutical Industries ADR gained 4.0% in the week to 14 August, taking its four-week advance to 14.8% and its 52-week return to 105.9%. The weekly Trend Signal remains active, and the stock sits 11.5% above its Trend Line, but Market Dynamics are mixed: activity pressure is negative at -0.40 while Relative Strength is positive at 13.14. Volume of 29.3M shares was only 1.1x the 13-week average and 0.7x the 52-week average, leaving participation short of a strong breakout confirmation.
- TEVA closed at $36.77, 96.9% of the way through its 52-week range and only 1.7% below the $37.39 high.
- The stock outpaced US Healthcare’s 0.2% weekly average and the US specialty and generic drug group’s 1.6% average with a 4.0% weekly gain.
- Trend state remains constructive, with the price 11.5% above the $32.97 weekly Trend Line and 51 of the past 52 weeks active.
- The signal stack is balanced rather than clean: Relative Strength is positive, but activity pressure is negative and there is no fresh activity-pressure buy signal.
- Valuation distance is a risk marker, with the close 86.0% above Sharemaestro Fair Value of $19.77.
Company analysis
The move in context
Price action keeps Teva near the top of its yearly range
Teva Pharmaceutical Industries ADR ended the week at $36.77, up 4.0%, leaving the stock just 1.7% below its 52-week high of $37.39. The move adds to a 14.8% four-week advance and keeps the 12-week return positive at 7.9%, although the shorter-term pace is stronger than the quarterly read. Over one year, the ADR has gained 105.9%, a large move for a $40.2B healthcare name and a reminder that expectations have already risen sharply.
The weekly Trend Signal remains active, with a three-week active streak and 51 active weeks across the past year. Price is 11.5% above the $32.97 Trend Line, so the technical backdrop remains constructive. The more stretched part of the picture is valuation distance: the close is 86.0% above Sharemaestro Fair Value of $19.77, which does not negate momentum but raises the bar for follow-through.
Healthcare context is supportive, but the industry breadth is uneven
Teva’s 4.0% weekly gain was well ahead of the US Healthcare average of 0.2% and also beat the US Drug Manufacturers - Specialty & Generic industry average of 1.6%. On a four-week basis, Teva’s 14.8% return also outpaced the sector’s 3.6% and the industry’s 6.6%, placing the ADR in the stronger end of both peer sets.
The breadth backdrop is less uniform. In US Healthcare, 57.0% of tracked names have active weekly trend signals and 75.0% show positive Market Dynamics, but only 40.0% have positive Relative Strength. The specialty and generic drug group is thinner, with just 37.0% trend breadth and 28.8% positive Relative Strength breadth. That makes Teva’s active trend and positive Relative Strength stand out, but it also means the industry is not offering broad confirmation.
Momentum is positive, but Market Dynamics are not fully aligned
The Sharemaestro setup reads as balanced, with a composite score of 67. Relative Strength is positive at 13.14 and has improved sharply over four weeks, placing Teva around the 72nd percentile within the broader US Healthcare peer set. That helps explain why the ADR has held near its high while many healthcare names show weaker relative participation.
The offset is activity pressure, which is negative at -0.40 and has weakened over the past four weeks. The signal state therefore is not a clean momentum confirmation: trend is active, price is above trend, and Relative Strength is supportive, but activity pressure shows no fresh buy signal. For a stock close to a 52-week ceiling, that mixed reading matters because failed follow-through can quickly turn into range fatigue.
Volume confirms interest, not conviction
Weekly volume reached 29.3M shares, above the 13-week average of 27.5M and equal to a 1.1x participation ratio. That is enough to show continued interest, especially after the prior week’s 1.0% gain, but it is still below the 52-week average of 40.9M. The strongest recent participation came on 31 July, when a 13.6% weekly gain traded 41.6M shares.
Risk remains two-sided. The 13-week volatility reading is 5.5%, close to the 52-week base of 5.6%, while the past 52 weeks show 32 up weeks against 20 down weeks. Average positive weeks have been larger than average negative weeks, at 4.9% versus -3.8%, but the distribution also includes six sharp-loss weeks. Next, investors should watch whether price can stay near the 52-week high with stronger volume, whether activity pressure turns back positive, and whether the $32.97 Trend Line remains comfortably below the market.
Peer comparison
How the wider group is behaving
Breadth shows how much of the sector or industry is participating. A company move is more convincing when its peers are improving too.
US Healthcare
100 tracked companiesAbove Trend Line57.0%
Positive Relative Strength40.0%
US Drug Manufacturers - Specialty & Generic
73 tracked companiesAbove Trend Line37.0%
Positive Relative Strength28.8%
Balanced view
What supports the case, and what could weaken it
What is working
- The trend backdrop is active with a 3-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Next-week expectancy is positive at 56.33% based on similar historical setup states.
- Activity pressure is constructive, supporting the smart-money activity read.
What needs caution
- Activity pressure is negative, which weakens the current setup.
- 4 reversal markers appear in the recent smart-money tape.
Research note
This article is for educational market research only and is not financial, investment, trading, tax, or legal advice. Sharemaestro does not make buy, sell, or hold recommendations.
Source and attribution
Source: Sharemaestro. Canonical article: https://sharemaestro.com/news/teva-doubles-negative-pressure-near-high/.
Follow new Sharemaestro research through the RSS feed or JSON feed.